Abstracts Archive - Page 1655 of 2607 - ACR Meeting Abstracts

Abstract Number: 833 • 2016 ACR/ARHP Annual Meeting
A Small Proportion of Patients with Systemic Sclerosis with Suspected Pulmonary Hypertension Meet the Published Inclusion/Exclusion Criteria for Two Systemic Sclerosis Associated Pulmonary Arterial Hypertension Screening Algorithms– Results from a Single Center Cohort
Amber Young¹, Victor Moles², Vivek Nagaraja³, Scott H. Visovatti⁴, Vallerie McLaughlin⁴ and Dinesh Khanna⁵, ¹Department of Internal Medicine, Division of Rheumatology, University of Michigan, Ann Arbor, MI, ²Department of Internal Medicine, Division of Cardiology, University of Michigan, Ann Arbor, MI, ³Department of Medicine [Division of Rheumatology], University of Toledo, Toledo, OH, ⁴Internal Medicine, Division of Cardiology, University of Michigan, Ann Arbor, MI, ⁵University of Michigan, Ann Arbor, MI
Background/Purpose: Pulmonary arterial hypertension (PAH) is one of the leading causes of mortality in patients with systemic sclerosis (SSc). Active screening detects SSc-PAH earlier and…
Abstract Number: 834 • 2016 ACR/ARHP Annual Meeting
Distinctive Clinical Phenotype of Anti-Centromere Antibody Positive Diffuse Systemic Sclerosis
Joana Caetano¹, Svetlana Nihtyanova², Jennifer Harvey³, Christopher P.Denton⁴ and Voon H. Ong⁵, ¹Department of Medicine IV, Systemic Immunomediated Diseases Unit, Fernando Fonseca Hospital, Amadora, Portugal, ²Centre for Rheumatology and Connective Tissue Diseases, University College London Medical School, Royal Free Hospital, London, United Kingdom, ³Clinical Immunology, Royal Free Hospital, London, United Kingdom, ⁴Centre of Rheumatology and Connective Tissue Diseases, University College London, London, United Kingdom, ⁵Rheumatology, UCL Division of Medicine, London, United Kingdom
Background/Purpose: Although anti-centromere antibodies (ACA) typically associate with limited cutaneous subset of systemic sclerosis (lcSSc) this reactivity is also seen in some cases with diffuse…
Abstract Number: 835 • 2016 ACR/ARHP Annual Meeting
A Normal Pulmonary Diffusion Capacity Is Rare in Pulmonary Artery Hypertension in Systemic Sclerosis
Rebecca Overbury¹, Tracy M. Frech², Maureen Murtaugh³, Virginia D. Steen⁴ and PHAROS investigators, ¹Internal Medicine and Pediatrics, University of Utah, Salt Lake City, UT, ²Division of Rheumatology, University of Utah, Salt Lake City, UT, ³University of Utah, Salt Lake, UT, ⁴Rheumatology, Georgetown University Medical Center, Washington, DC
Background/Purpose: Methods: Results: > 70% (mean 78%) versus 191 patients (94.6%) who had a low DLCO <70% (mean 39%). There was no difference…
Abstract Number: 836 • 2016 ACR/ARHP Annual Meeting
Comprehensive Characterization of Calcinosis in a Multicenter International Cohort of Patients with Systemic Sclerosis
Antonia Valenzuela^1,2, Jessica K. Gordon³, Tatiana Sofia Rodriguez-Reyna⁴, Susanna Proudman^5,6, Murray Baron⁷, Monique Hinchcliff⁸, Dinesh Khanna⁹, Amber Young¹⁰, Flavia V. Castelino¹¹, Sara R. Schoenfeld¹², Virginia D. Steen¹³, David Fiorentino¹⁴ and Lorinda Chung¹⁵, ¹Division of Immunology and Rheumatology, Stanford University School of Medicine, Palo Alto, CA, ²Stanford University School of Medicine, Stanford, CA, ³Rheumatology, Hospital for Special Surgery, New York, NY, ⁴Immunology and Rheumatology, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico, ⁵Rheumatology Unit, Royal Adelaide Hospital, Adelaide, Australia, ⁶Discipline of Medicine, University of Adelaide, Adelaide, Australia, ⁷Rheumatology, McGill University, Jewish General Hospital, Montreal, QC, Canada, ⁸Northwestern University, Feinberg School of Medicine Scleroderma Program, Chicago, IL, ⁹University of Michigan, Ann Arbor, MI, ¹⁰Department of Internal Medicine, Division of Rheumatology, University of Michigan, Ann Arbor, MI, ¹¹Rheumatology, Allergy, Immunology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, ¹²Rheumatology Unit, Massachusetts General Hospital, Harvard Medical School, Boston, MA, ¹³Rheumatology, Georgetown University Medical Center, Washington, DC, ¹⁴Department of Dermatology, Stanford University School of Medicine, Palo Alto, CA, ¹⁵Rheumatology, Stanford University Medical Center, Palo Alto, CA
Background/Purpose: Calcinosis cutis is a debilitating complication of systemic sclerosis (SSc) affecting one quarter of patients. Repetitive trauma may be involved in the pathogenesis of…
Abstract Number: 837 • 2016 ACR/ARHP Annual Meeting
Development of a Skin-Specific Scleroderma Patient Reported Outcome Instrument
Ada Man¹, Jeannette K. Correa², Jessica Ziemek³, David T. Felson⁴ and Robert Lafyatis⁵, ¹Rheumatology, University of Manitoba, Winnipeg, MB, Canada, ²Psychology, Boston University, Boston, MA, ³Rheumatology, Boston University, Boston, MA, ⁴Clinical Epidemiology Unit, Boston University School of Medicine, Boston, MA, ⁵Division of Rheumatology and Clinical Immunology, University of Pittsburgh School of Medicine, Pittsburgh, PA
Background/Purpose: Skin fibrosis is the hallmark of SSc and may lead to significantly reduced quality of life in ways that may not be directly proportional…
Abstract Number: 838 • 2016 ACR/ARHP Annual Meeting
Esophageal Dysmotility and Interstitial Lung Disease in Patients with Scleroderma: A Retrospective Study
Shweta Kishore¹, Santhanam Lakshminarayanan¹, Chia-Ling Kuo² and Ranadeep Mandhadi¹, ¹Division of Rheumatology, University of Connecticut, Farmington, CT, ²Department of Community Medicine and Health Care, University of Connecticut, Farmington, CT
Background/Purpose: Systemic sclerosis (SSc) is a connective tissue disease with pulmonary involvement seen in 75% of patients and esophageal involvement in 90% of the patients.…
Abstract Number: 839 • 2016 ACR/ARHP Annual Meeting
Immunosuppression Does Not Prevent Severe Gastrointestinal Disease in Systemic Sclerosis
Nicolas Richard¹, Marie Hudson², Mianbo Wang³, Murray Baron⁴, Genevieve Gyger¹ and Canadian Scleroderma Research Group, ¹McGill University, Jewish General Hospital, Montreal, QC, Canada, ²Medicine/Rheumatology, Jewish General Hospital, Lady Davis Research Institute, Montreal, QC, Canada, ³Lady Davis Institute for Medical Research, Montreal, QC, Canada, ⁴Rheumatology, McGill University, Jewish General Hospital, Montreal, QC, Canada
Background/Purpose: Severe gastrointestinal (GI) disease is associated with considerable morbidity and high mortality in systemic sclerosis (SSc). There are no known preventative treatments. We wished…
Abstract Number: 840 • 2016 ACR/ARHP Annual Meeting
Time Trends in Incidence and Mortality of Systemic Sclerosis in Denmark from 1995-2011: A Nationwide Cohort Study
Sheraz Butt¹, Charlotte Andersson², Søren Jacobsen³, Gunnar Gislason⁴ and Christian Torp-Pedersen⁵, ¹Department of Medicine, Glostrup Hospital, Glostrup, Denmark, ²Department of Medicine, Glostrup Hospital, Copenhagen, Denmark, ³Center for Rheumatology and Spine Diseases, Rigshospitalet - Glostrup, University of Copenhagen, Denmark, Glostrup, Denmark, ⁴Department of Cardiology, Gentofte Hospital, Copenhagen, Denmark, ⁵Aalborg University, Aalborg, Denmark
Time Trends In Incidence And Mortality Of Systemic Sclerosis In Denmark From 1995-2011: A Nationwide Cohort Study Background/Purpose: Epidemiological studies have documented an increasing incidence…
Abstract Number: 841 • 2016 ACR/ARHP Annual Meeting
Low Nucleoside Triphosphate Pyrophosphohydrolase Activity Contributes to Pathologic Mineralization in Systemic Sclerosis
Yue Ding¹, Supraja Yeturi¹, Claudia Gohr¹, Mary Ellen Csuka¹ and Ann K. Rosenthal^2,3, ¹Medicine, Medical College of Wisconsin, Milwaukee, WI, ²Division of Rheumatology, Medical College of Wisconsin, Milwaukee, WI, ³Medicine, Clement J. Zablocki VA Medical Center, Milwaukee, WI
Background/Purpose: Calcinosis is a major source of morbidity in patients with systemic sclerosis (SS). In addition, increased coronary calcification has been reported in patients with…
Abstract Number: 842 • 2016 ACR/ARHP Annual Meeting
Aminaphtone Treatment Increases Skin Blood Perfusion and Related Clinical Symptoms in Patients Affected By Raynaud’s Phenomenon: A Pilot Study Based on Laser Speckle Contrast Analysis
Barbara Ruaro, Sabrina Paolino, Carmen Pizzorni, Maurizio Cutolo and Alberto Sulli, Research Laboratory and Academic Division of Clinical Rheumatology, Department of Internal Medicine, University of Genova, Genoa, Italy, Genova, Italy
Background/Purpose: Aminaphtone is an oral vasoactive drug used to treat microvascular impairement since 30 years, and recently suggested to down-regulate endothelin-1 production by endothelial cells,…
Abstract Number: 843 • 2016 ACR/ARHP Annual Meeting
Forced Vital Capacity Predicts Outcome in Scleroderma Associated Interstitial Lung Disease with Concomitant Pulmonary Hypertension: Data from the Pharos Registry
Joyce Sujin Lee¹, Jessica K. Gordon², Jackie Szymonifka³, Virginia Steen⁴ and Aryeh Fischer⁵, ¹SOM-MED, University of Colorado, Denver - Anschutz Medical Campus, Aurora, CO, ²Rheumatology, Hospital for Special Surgery, New York, NY, ³Epidemiology and Biostatistics, Hospital for Special Surgery, New York, NY, ⁴Georgetown University School of Medicine, Washington, DC, ⁵Medicine / Center for Lungs and Breathing, University of Colorado School of Medicine, Aurora, CO
Forced vital capacity predicts outcome in scleroderma associated interstitial lung disease with concomitant pulmonary hypertension: Data from the PHAROS registry Background/Purpose: Interstitial lung disease…
Abstract Number: 844 • 2016 ACR/ARHP Annual Meeting
Bardoxolone Methyl Produces Durable Benefits in Participants with Pulmonary Arterial Hypertension: Data from an Open-Label Extension Study
Ron Oudiz¹, Colin Meyer², Melanie Chin², Jeremy Feldman³, Angie Goldsberry², John McConnell⁴, Peter A. McCullough⁵, Megan O'Grady², Victor Tapson⁶, Fernando Torres⁷, Aaron B. Waxman⁸ and R. James White⁹, ¹Los Angeles Biomedical Research Inst. at Harbor-UCLA Medical Center, Torrance, CA, ²Reata Pharmaceuticals, Irving, TX, ³Arizona Pulmonary Specialists, Phoenix, AZ, ⁴Kentuckiana Pulmonary Associates, Louisville, KY, ⁵Baylor University Medical Center, Dallas, TX, ⁶Cedars-Sinai Medical Center, Los Angeles, CA, ⁷University of Texas, Southwestern Medical Center, Dallas, TX, ⁸Harvard Medical School, Boston, MA, ⁹University of Rochester Medical Center, Rochester, NY
Background/Purpose: Bardoxolone methyl (BARD), an activator of the transcription factor Nrf2, and inhibitor of NF-kB, targets dysfunctional inflammatory, metabolic, and bioenergetic pathways. In an initial…
Abstract Number: 845 • 2016 ACR/ARHP Annual Meeting
Current Use of Off-Label Therapies in Systemic Sclerosis-Associated Interstitial Lung Disease
Elise Siegert¹, Dörte Huscher², Ulf Müller-Ladner³, Veronika K. Jaeger⁴, Ulrich A. Walker⁴, Marc Frerix⁵, László Czirják⁶, Francesco Del Galdo⁷, Gabriele Valentini⁸, Marco Matucci-Cerinic⁹, Yannick Allanore¹⁰, Oliver Distler¹¹, Christopher Denton¹², Gabriela Riemekasten¹³ and EUSTAR co-authors, ¹Rheumatology and Clinical Immunology, Charité – University Medicine Berlin, Berlin, Germany, ²Epidemiology, German Rheumatism Research Centre, Berlin, Germany, ³Department of Internal Medicine and Rheumatology, Justus-Liebig-University Giessen, Kerckhoff-Klinik, Bad Nauheim, Germany, ⁴Department of Rheumatology, University Hospital Basel, Basel, Switzerland, ⁵Department of Rheumatology and Clinical Immunology, Justus-Liebig-University Giessen, Kerckhoff-Klinik, Bad Nauheim, Germany, ⁶Department of Rheumatology and Immunology, University of Pécs, Faculty of Medicine, Pécs, Hungary, ⁷Musculoskeletal Diseases, Scleroderma Research Program, Leeds Institute of Molecular Medicine, Division of Musculoskeletal Diseases, University of Leeds, Leeds, United Kingdom, ⁸Internal and Experimental Medicine, Rheumatology Unit, Second University of Naples, Naples, Italy, ⁹Department of Medicine, Division of Rheumatology, University of Florence, Florence, Italy, ¹⁰Rheumatology, Paris Descartes University, Rheumatology A department, Cochin Hospital, Paris, France, ¹¹Department of Rheumatology, University Hospital Zurich, Zurich, Switzerland, ¹²Division of Medicine, Centre for Rheumatology and Connective Tissue Disease, University College London, London, United Kingdom, ¹³Department of Rheumatology, Universitatsklinikum Schleswig-Holstein, Lubeck, Germany
Background/Purpose: Systemic Sclerosis (SSc) is a connective tissue disease that is often complicated by secondary interstitial lung disease (SSc-ILD). Due to its high morbidity and…
Abstract Number: 846 • 2016 ACR/ARHP Annual Meeting
Progression of Left Ventricular Myocardial Dysfunction in Systemic Sclerosis: Using Speckle Tracking Strain Echocardiography to Identify Patients at Risk
Susanne Van Wijngaarden¹, Samira Ben Said- Bouyeri², Maarten K. Ninaber³, J.J. Bax¹, V. Delgado¹, Jeska K. de Vries-Bouwstra⁴ and Nina Ajmone Marsan¹, ¹Heart and Lung Center, Leiden University Medical Center, Leiden, Netherlands, ²Rheumatology, Leiden University Medical Center, Leiden, Netherlands, ³Heart and Lung Center; Pulmonology, Leiden University Medical Center, Leiden, Netherlands, ⁴Department of Rheumatology, Leiden University Medical Center, Leiden, Netherlands
Background/Purpose: Cardiac involvement is a main cause of mortality in systemic sclerosis, although reported prevalence of cardiac involvement is low and detection of cardiac involvement…
Abstract Number: 847 • 2016 ACR/ARHP Annual Meeting
Forced Vital Capacity Predicts Lung Fibrosis Progression and Mortality in Systemic Sclerosis
Anna Hoffmann-Vold¹, Elizabeth R. Volkmann², Oyvind Midtvedt³, Torhild Garen³, Anders Heiervang Tennøe³, Trond Mogens Aalokken⁴, May Brit Lund⁵ and Øyvind Molberg³, ¹Division of Rheumatology, Oslo University Hospital, Oslo, Norway, ²University of California, Los Angeles, David Geffen School of Medicine, Los Angeles, CA, ³Rheumatology, Oslo University Hospital, Oslo, Norway, ⁴Radiology, Oslo University Hospital, Oslo, Norway, ⁵Respiratory Medicine, Oslo University Hospital, Oslo, Norway
Background/Purpose: Systemic sclerosis (SSc) carries high risk for progressive interstitial lung disease (ILD), but there are no valid methods for early detection of SSc-ILD or…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].